MENS: Jyong Biotech Corp Kompaniya qiymatining sof foydaga nisbati

Jyong Biotech Limited (MENS) korporativ emblemasi va logotipi

GURU.Markets platformasida Jyong Biotech Ltd (MENS) uchun P/E tendentsiyasini tahlil qilib, biz -27.50 joriy metrika darajasi vazifasini bajarishini qayd etamiz. Jyong Biotech Ltd moliyaviy barqarorligi R&D xarajatlari tufayli ayni paytda minimal darajada. O'sish Osiyo markazlari bilan hamkorlikka va distribyutsiya sotib olish kelishuvlariga asoslangan; biroq, o'simliklar asosidagi dori vositalari uchun tartibga soluvchi tasdiqlash jarayonlarining cho'zilishi va sintetik analoglarning bosimi sezilarli xatarlarni yuzaga keltirmoqda.

MENS Jyong Bio: Narx-foyda koeffitsiyenti 21.06.2025 - 15.11.2026 oraligʻida

Jyong Biotech Limited (MENS) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Jyong Biotech Limited - MENS
Jyong Biotech yetakchi tovari

Himoyaviy portfelni shakllantirishda fundamental skrining korporatsiyaning real daromadining bir birligi uchun xarajatni belgilovchi bozor kapitalizatsiyasining sof foydaga nisbatiga tayanadi. Biologlarning yuqori malakali xodimlari va laboratoriyalarga investitsiya kiritadigan Jyong Biotech Ltd (MENS) uchun kompaniyaning tarixiy P/E dinamikasi investorlarga manipulyativ narx tebranishlarini filtrlash va yirik ishtirokchilar tomonidan yashirin aktivlar to'planishini aniqlash imkonini beradi.

Raqobatdosh kompaniyalar tahlili

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Ligand Pharmaceuticals Incorporated LGND|Amneal (AMRX) - Kapitalizatsiyaning foydaga nisbati|PRGO: Narx-foyda koeffitsiyenti|Alvotech SA - Bozor narxining sof foydaga nisbati|LQDA: P/E multiplikatori|Galapagos Genomics - Kompaniya qiymatining sof foydaga nisbati|ANIP (ANI Pharmaceuticals Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati mannkindcorp.com MNKD|Narxning foydaga nisbati Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SPRY (ARS Pharmaceuticals Inc)|Bozor narxining sof foydaga nisbati TBPH (Theravance)|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)